Zhejiang Orient Gene Biotech Co., Ltd (SHA:688298)
China · Delayed Price · Currency is CNY 22.93
-0.34 (-1.46%)
Mar 9, 2026, 3:00 PM CST
SHA:688298 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 958.99 | 811.28 | 812.34 | 8,741 | 10,152 |
Other Revenue | - | 16.64 | 7.81 | 27.23 | 16.98 |
| 958.99 | 827.92 | 820.16 | 8,768 | 10,169 | |
Revenue Growth (YoY) | 15.83% | 0.95% | -90.65% | -13.78% | 211.43% |
Cost of Revenue | - | 659.26 | 640.51 | 5,158 | 2,682 |
Gross Profit | 958.99 | 168.66 | 179.64 | 3,610 | 7,487 |
Selling, General & Admin | - | 597.01 | 534.55 | 755.81 | 1,133 |
Research & Development | - | 290.49 | 260.86 | 511.56 | 428.52 |
Other Operating Expenses | 1,535 | 14.46 | 14.22 | 89.16 | 72.75 |
Operating Expenses | 1,535 | 932.06 | 839.8 | 1,350 | 1,667 |
Operating Income | -575.82 | -763.4 | -660.15 | 2,260 | 5,820 |
Interest Expense | - | -19.25 | -18.12 | -6.97 | -0.94 |
Interest & Investment Income | - | 222.78 | 249.68 | 122.87 | 46.02 |
Currency Exchange Gain (Loss) | - | 44.91 | 87.17 | 495.21 | -99.72 |
Other Non Operating Income (Expenses) | -1.25 | -0.36 | 1.5 | -2.44 | -2.09 |
EBT Excluding Unusual Items | -577.07 | -515.32 | -339.92 | 2,869 | 5,763 |
Impairment of Goodwill | - | -55.58 | -57.31 | -15.41 | - |
Gain (Loss) on Sale of Investments | - | 10.65 | -8.99 | 1.66 | 0.04 |
Gain (Loss) on Sale of Assets | - | 0.82 | -0.64 | -0.13 | -0.04 |
Asset Writedown | - | -26 | -6.09 | -351.04 | - |
Other Unusual Items | - | 0.12 | 8.72 | -33.16 | 6.71 |
Pretax Income | -577.07 | -585.31 | -404.23 | 2,471 | 5,770 |
Income Tax Expense | -13.45 | -16.49 | 14.04 | 373.32 | 829.32 |
Earnings From Continuing Operations | -563.62 | -568.82 | -418.27 | 2,097 | 4,941 |
Minority Interest in Earnings | - | 39.8 | 20.69 | -29.72 | -20.46 |
Net Income | -563.62 | -529.02 | -397.58 | 2,068 | 4,920 |
Net Income to Common | -563.62 | -529.02 | -397.58 | 2,068 | 4,920 |
Net Income Growth | - | - | - | -57.98% | 193.33% |
Shares Outstanding (Basic) | 192 | 197 | 202 | 202 | 202 |
Shares Outstanding (Diluted) | 192 | 197 | 202 | 202 | 202 |
Shares Change (YoY) | -2.19% | -2.56% | 0.13% | -0.02% | 2.16% |
EPS (Basic) | -2.93 | -2.69 | -1.97 | 10.26 | 24.40 |
EPS (Diluted) | -2.93 | -2.69 | -1.97 | 10.26 | 24.40 |
EPS Growth | - | - | - | -57.97% | 187.12% |
Free Cash Flow | - | -1,272 | -2,642 | 1,944 | 4,696 |
Free Cash Flow Per Share | - | -6.47 | -13.09 | 9.64 | 23.29 |
Dividend Per Share | - | - | - | 1.667 | 3.679 |
Dividend Growth | - | - | - | -54.69% | 47.14% |
Gross Margin | 100.00% | 20.37% | 21.90% | 41.18% | 73.63% |
Operating Margin | -60.04% | -92.21% | -80.49% | 25.78% | 57.23% |
Profit Margin | -58.77% | -63.90% | -48.48% | 23.58% | 48.38% |
Free Cash Flow Margin | - | -153.69% | -322.09% | 22.17% | 46.18% |
EBITDA | -396.62 | -584.2 | -508.83 | 2,338 | 5,849 |
EBITDA Margin | -41.36% | -70.56% | -62.04% | 26.66% | 57.52% |
D&A For EBITDA | 179.2 | 179.2 | 151.33 | 77.84 | 28.77 |
EBIT | -575.82 | -763.4 | -660.15 | 2,260 | 5,820 |
EBIT Margin | -60.04% | -92.21% | -80.49% | 25.78% | 57.23% |
Effective Tax Rate | - | - | - | 15.11% | 14.37% |
Revenue as Reported | - | 827.92 | 820.16 | 8,768 | 10,169 |
Advertising Expenses | - | 22.14 | 24.52 | 13.47 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.